Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Growth in Short Interest

Key Points

• Basilea Pharmaceutica AG experienced a significant increase in short interest, rising by 571.4% in August, with totals reaching 4,700 shares compared to 700 shares at the end of July.
• The company's stock price remained stable at $67.75, with a 52-week trading range of $47.50 to $67.75.
• Basilea Pharmaceutica focuses on developing treatments in oncology and anti-infectives, with its key product, Cresemba, targeting severe fungal infections.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 4,700 shares, anincreaseof571.4% from the July 31st total of 700 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Basilea Pharmaceutica Stock Performance

BPMUF remained flat at $67.75 during trading hours on Friday. The business's 50 day simple moving average is $64.86 and its two-hundred day simple moving average is $56.39. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.85 and a quick ratio of 4.16. Basilea Pharmaceutica has a 52 week low of $47.50 and a 52 week high of $67.75.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.